STSaravanabhavan Thangavel

Saravanabhavan Thangavel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saravanabhavan Thangavel has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Vigneshwaran Venkatesan

    Centre for Stem Cell Research (a unit of BRIC-inStem, Bengaluru), Christian Medical College Campus, Vellore, India

    10 shared publications
  • Prathibha Babu

    Centre for Stem Cell Research (CSCR), A Unit of InStem Bengaluru, Christian Medical College Campus, Vellore, Tamil Nadu 632002, India

    8 shared publications
  • Alok Srivastava

    Centre for Stem Cell Research (CSCR), a Unit of InStem Bengaluru, Christian Medical College Campus, Vellore, India

    7 shared publications
  • Abisha Crystal Christopher

    Centre for Stem Cell Research (CSCR), A Unit of InStem Bengaluru, Christian Medical College Campus, Vellore, Tamil Nadu 632002, India

    6 shared publications
  • Kumarasamypet Murugesan Mohankumar

    Centre for Stem Cell Research (CSCR), A Unit of BRIC-InStem Bengaluru, Christian Medical College Campus, Vellore, Tamil Nadu, India

    5 shared publications
  • Manoj Kumar K. Azhagiri

    Centre for Stem Cell Research (CSCR), A Unit of BRIC-InStem Bengaluru, Christian Medical College Campus, Vellore, Tamil Nadu, India

    5 shared publications

Latest Publications

  • Open Access

    Guide RNA truncation as a tunable approach for modulating base editing outcomes

    by Anila George, Kirti Prasad, Poornasree Sadanandan, Srujan Marepally, Saravanabhavan Thangavel, Kumarasamypet Murugesan Mohankumar

    Base editing enables programmable nucleotide conversion but can be limited by bystander editing and unintended genomic alterations. Here, we investigated guide RNA (gRNA) truncation as a strategy to modulate base editing outcomes. On editing across multiple genomic loci using ABE8e in HUDEP-2 cells, we found that truncated gRNAs retained measurable editing activity at lengths as short as 15 nucleotides, although activity depended strongly on target sequence, gRNA length, and delivery method. Importantly, truncation altered editing efficiencies at individual nucleotides within the editing window, enabling selective reduction of bystander editing while preserving on-target conversion at several loci, including a therapeutically relevant HbE target. Truncated gRNAs also eliminated detectable large deletions at homologous globin loci, consistent with loss of Cas9 nickase activity at short gRNAs lengths. Similar length dependent effects were observed with cytosine base editing, PAM relaxed ABE8e, and in primary hematopoietic stem and progenitor cells (HSPCs), although the optimal gRNA length varied between contexts. Together, these findings establish gRNA length as an additional parameter for tuning nucleotide level base editing outcomes and reducing bystander editing.

  • Open Access

    HLF and hTERT cooperatively enable partial immortalization of human hematopoietic stem and progenitor cells

    by Manoj Kumar K. Azhagiri, Els Verhoeyen, Kumarasamypet Murugesan Mohankumar, Srujan Kumar Marepally, Vigneshwaran Venkatesan, Saravanabhavan Thangavel

    Hematopoietic stem and progenitor cells (HSPCs), residing at the apex of the hematopoietic hierarchy, are critical for the generation of all blood and immune cell lineages. This unique capacity makes HSPCs indispensable for advancing cell and gene therapies aimed at correcting defects across hematopoietic lineages. However, current gene therapy development is constrained by the requirement for fresh primary HSPCs, hindering the breadth of preclinical validation. While several hematopoietic lineages have been immortalized to facilitate research, the stable immortalization of human HSPCs remains unreported. Here, we demonstrate that combinatorial overexpression of HLF, a key regulator of stem cell maintenance, and hTERT, a telomere maintenance factor in primitive human HSCs, supported by BaEV-mediated transduction and optimized culture conditions, yields partial immortalization of HSPCs. These genetically modified cells sustained for up to 70 days and exhibited limited differentiation towards erythroid, megakaryocytic, and macrophage lineages. Our model establishes a protocol for generating primary cell like context for testing gene therapy strategies, enabling functional assessment in both undifferentiated HSPCs and their lineage-committed progeny.

  • Open Access

    Engineering biomimetic bone marrow niche with gene modified mesenchymal stromal cells for ex vivo culture of human hematopoietic stem and progenitor cells

    by Sevanthy Suresh, Vigneshwaran Venkatesan, Manoj Kumar K. Azhagiri, Gokulnath Mahalingam, Prathibha Babu Chandraprabha, Mohankumar K. Murugesan, Sanjay Kumar, Saravanabhavan Thangavel, Srujan Marepally

    Hematopoietic Stem and Progenitor Cells (HSPCs) gene therapy has shown significant progress, with commercial approval for at least four distinct haematological disorders, and poised for a rapid expansion in the upcoming years. Despite these advancements, the ex vivo culture of HSPCs continues to present significant challenges. The stress induced by ex vivo culture can negatively impact transplantation outcomes, while the need for exogenous cytokine supplementation contributes to the high costs associated with gene therapy products. We developed genetically modified human bone marrow MSCs (GM-MSCs) secreting cytokines such as Stem cell factor (SCF), Thrombopoietin (TPO), FMS-like tyrosine kinase-3-ligand (FLT3L), and Interleukin-3 (IL3), closely resembling bone marrow cellular niche to augment HSPCs culture. HSPCs proliferate on GM-MSCs akin to standard conditions, devoid of external cytokine supplementation and these HSPCs retain their stem cell characteristics, colony-forming potential, stemness gene signatures, and capacity for long-term multilineage reconstitution in NBSGW mice. We demonstrate that our biomimetic feeder layer supports and alleviates stress associated with Homology Directed Repair (HDR) mediated gene-editing of HSPCs for fetal haemoglobin reactivation for a potential application in β-hemoglobinopathies gene therapy. Our GM-MSCs offer a compelling alternative to traditional cytokine supplementation by establishing a biomimetic bone marrow niche that fosters HSPC expansion while maintaining their stemness. These findings underscore the potential of engineered MSCs to revolutionize ex vivo HSPCs culture, ultimately enhancing their therapeutic value for gene therapy applications.


  • Open Access

    Advancing Precision Medicine: Recent Innovations in Gene Editing Technologies

    by Abhijith Koodamvetty, Saravanabhavan Thangavel

    The advent of gene editing has significantly advanced the field of medicine, opening new frontiers in the treatment of genetic disorders, cancer, and infectious diseases. Gene editing technology remains a dynamic and promising area of research and development. Recent advancements in protein and RNA engineering within this field have addressed critical issues such as imprecise edits, poor editing efficiency, and off‐target effects. Advancements in delivery methods have allowed the achievement of therapeutic or even selection‐free gene editing efficiency with reduced toxicity in primary cells, thereby enhancing the safety and efficacy of gene manipulation. This progress paves the way for transformative changes in molecular biology, medicine, and other fields. This review provides a comprehensive overview of the advancements in gene editing techniques, focusing on prime editor proteins and their engineered variants. It also explores alternative systems that expand the toolkit for precise genomic modifications and highlights the potential of these innovations in treating hematological disorders, while also discussing the limitations and challenges that remain.


  • Open Access

    Enhanced fetal hemoglobin production via dual-beneficial mutation editing of the HBG promoter in hematopoietic stem and progenitor cells for β-hemoglobinopathies

    by Prathibha Babu Chandraprabha, Manoj Kumar K. Azhagiri, Vigneshwaran Venkatesan, Wendy Magis, Kirti Prasad, Sevanthy Suresh, Aswin Anand Pai, Srujan Marepally, Alok Srivastava, Kumarasamypet Murugesan Mohankumar, et al.

    Sickle cell disease (SCD) and β-thalassemia patients with elevated gamma globin (HBG1/G2) levels exhibit mild or no symptoms. To recapitulate this natural phenomenon, the most coveted gene therapy approach is to edit the regulatory sequences of HBG1/G2 to reactivate them. By editing more than one regulatory sequence in the HBG promoter, the production of fetal hemoglobin (HbF) can be significantly increased. However, achieving this goal requires precise nucleotide conversions in hematopoietic stem and progenitor cells (HSPCs) at therapeutic efficiency, which remains a challenge. We employed Cas9 RNP-ssODN-mediated homology-directed repair (HDR) gene editing to mimic two naturally occurring HBG promoter point mutations; -175T > C, associated with high HbF levels, and −158 C > T, a common polymorphism in the Indian population that induces HbF under erythropoietic stress, in HSPCs. Asymmetric, nontarget ssODN induced high rates of complete HDR conversions, with at least 15% of HSPCs exhibiting both the −175T > C and −158 C > T mutations. Optimized conditions and treatment with the small molecule AZD-7648 increased this rate, with up to 57% of long-term engrafting human HSPCs in NBSGW mice containing at least one beneficial mutation. Functionally, in vivo erythroblasts exhibited high levels of HbF, which was sufficient to reverse the cellular phenotype of β-thalassemia. Further support through bone marrow MSC co-culture boosted complete HDR conversion rates to exceed 80%, with minimal InDels, improved cell viability, and induced fetal hemoglobin levels similar to those of Cas9 RNP-mediated indels at BCL11A enhancer and HBG promoter. Cas9 RNP-ssODN-based nucleotide conversion at the HBG promoter offers a promising gene therapy approach to ameliorate the phenotypes of β-thalassemia and SCD. The developed approach can simplify and broaden applications that require the cointroduction of multiple nucleotide modifications in HSPCs.


  • Open Access

    Endocytosis as a critical regulator of hematopoietic stem cell fate —implications for hematopoietic stem cell and gene therapy

    by Prathibha Babu Chandraprabha, Saravanabhavan Thangavel

    Hematopoietic stem cells (HSCs) have emerged as one of the most therapeutically significant adult stem cells, paving way for a range of novel curative regimens over decades. HSCs are transplanted, either directly or post restorative genetic engineering in order to repopulate a healthy hematopoietic homeostasis in patients with disorders affecting the blood and immune cells. Despite being an extensively studied system, the maintenance and expansion of functional HSCs ex vivo remains a major bottleneck. The challenge primarily stems from difficulties in reproducing HSC self-renewal divisions and gradual depletion of stemness characters, in vitro. Refining the in vitro culture can be particularly beneficial in the case of cord blood HSCs (CB-HSCs), as inadequate numbers in a single umbilical cord limits its therapeutic potential. In recent years, molecular dissection of HSC stemness has significantly improved in vitro hematopoietic stem and progenitor cells (HSPCs) culture. Despite such significant progress, lacunae exist in fully understanding all the underlying mechanisms and their interplay active in bona fide HSCs, and how it transforms when cells proliferate in culture. A new groundbreaking study titled “MYCT1 controls environmental sensing in human haematopoietic stem cells”, published in Nature in June 2024, sheds light on this complex field. Through a series of experiments, including knock-down, overexpression, single-cell RNA sequencing, and transplantation, the study identifies a previously unknown role of the MYC target 1 (MYCT1) protein in HSC maintenance. This protein acts as a crucial regulator of human HSCs, with high expression in primitive HSCs and subsequently downregulated during ex vivo culture. The study reveals that MYCT1 plays a vital role in moderating endocytosis and environmental sensing in HSCs, processes thereby essential for maintaining HSC stemness and function. This commentary will discuss the implications of the new findings for cord blood expansion in cell therapies and HSPC culture for gene therapy applications, providing valuable insights for the field of hematopoietic regenerative medicine.


  • Open Access

    Editing of highly homologous gamma-globin genes by nickase deficient Base Editor mitigates large intergenic deletions

    by Anila George, Nithin Sam Ravi, B Vaishnavi, Srujan Marepally, Saravanbhavan Thangavel, Shaji R Velayudhan, Alok Srivastava, Kumarasamypet Murugesan Mohankumar

    Base editing in gamma-globin promoter is a promising approach for reactivation of fetal-hemoglobin. Recent studies have shown that base editing could result in genotoxic events at the gamma globin locus including 4.9 kb large deletion of intervening region due to nicking in the paralogous HBG 1 and HBG 2 genes. Although the deletion frequency is less than what is observed with Cas9, it could diminish the therapeutic potential. We sought to evaluate if large deletion could be overcome while maintaining the editing efficiency by replacing the nCas9 of ABE8e with a catalytically inactive deadCas9 (dCas9). Using 3 therapeutically relevant gRNAs targeting the gamma globin promoter, we performed a comprehensive evaluation of the editing outcome and frequency of large deletion using dCas9, nCas9, dCas9-ABE8e and nCas9-ABE8e. Our findings indicate that while nicking in itself induced large deletions, the frequency reduced upon efficient base editing. Notably, there was no appreciable deletion with the use of dCas9-ABE8e making it a safer approach, in terms of genome integrity, for therapeutic genome editing in the gamma-globin locus. Further, we also demonstrate that dCas9 ABE8e can edit efficiently in primary human CD34+ hematopoietic stem and progenitor cells (HSPCs) to achieve therapeutic benefits.

  • Open Access

    Current approaches and potential challenges in the delivery of gene editing cargos into hematopoietic stem and progenitor cells

    by Ramya Murugesan, Karthik V. Karuppusamy, Srujan Marepally, Saravanabhavan Thangavel

    Advancements in gene delivery and editing have expanded the applications of autologous hematopoietic stem and progenitor cells (HSPCs) for the treatment of monogenic and acquired diseases. The gene editing toolbox is growing, and the ability to achieve gene editing with mRNA or protein delivered intracellularly by vehicles, such as electroporation and nanoparticles, has highlighted the potential of gene editing in HSPCs. Ongoing phase I/II clinical trials with gene-edited HSPCs for β-hemoglobinopathies provide hope for treating monogenic diseases. The development of safe and efficient gene editing reagents and their delivery into hard-to-transfect HSPCs have been critical drivers in the rapid translation of HSPC gene editing into clinical studies. This review article summarizes the available payloads and delivery vehicles for gene editing HSPCs and their potential impact on therapeutic applications.


  • Open Access

    Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathies

    by Vigneshwaran Venkatesan, Abisha Crystal Christopher, Manuel Rhiel, Manoj Kumar K. Azhagiri, Prathibha Babu, Kaivalya Walavalkar, Bharath Saravanan, Geoffroy Andrieux, Sumathi Rangaraj, Saranya Srinivasan, et al.


  • Open Access

    Diosgenin enhances liposome-enabled nucleic acid delivery and CRISPR/Cas9-mediated gene editing by modulating endocytic pathways

    by Brijesh Lohchania, Abisha Crystal Christopher, Porkizhi Arjunan, Gokulnath Mahalingam, Durga Kathirvelu, Aishwarya Prasannan, Vigneshwaran Venkatesan, Pankaj Taneja, Mohan Kumar Km, Saravanabhavan Thangavel, et al.

    The CRISPR/Cas9 system holds great promise in treating genetic diseases, owing to its safe and precise genome editing. However, the major challenges to implementing the technology in clinics lie in transiently limiting the expression of genome editing factors and achieving therapeutically relevant frequencies with fidelity. Recent findings revealed that non-viral vectors could be a potential alternative delivery system to overcome these limitations. In our previous research, we demonstrated that liposomal formulations with amide linker-based cationic lipids and cholesterol were found to be effective in delivering a variety of nucleic acids. In the current study, we screened steroidal sapogenins as an alternative co-lipid to cholesterol in cationic liposomal formulations and found that liposomes with diosgenin (AD, Amide lipid: Diosgenin) further improved nucleic acid delivery efficacy, in particular, delivering Cas9 pDNA and mRNA for efficient genome editing at multiple loci, including AAVS1 and HBB, when compared to amide cholesterol. Mechanistic insights into the endocytosis of lipoplexes revealed that diosgenin facilitated the lipoplexes’ cholesterol-independent and clathrin-mediated endocytosis, which in turn leads to increased intracellular delivery. Our study identifies diosgenin-doped liposomes as an efficient tool to deliver CRISPR/Cas9 system.